Covid-19: Efectos de la Azitromicina/Hidroxicloroquina/Ivermectina en pacientes ambulatorios y hospitalizados

Universidad Médica Pinareña

View Publication Info
 
 
Field Value
 
Title Covid-19: Efectos de la Azitromicina/Hidroxicloroquina/Ivermectina en pacientes ambulatorios y hospitalizados
 
Creator MEJÍA ZAMBRANO, HENRY WILLIAMS
RAMOS CALSÍN, LIVIA YOLANDA
 
Subject Covid-19; Sars-Cov-2; Azitromicina; Hidroxicloroquina; Ivermectina
 
Description Introducción: A finales del año 2019 surgió el brote de un nuevo coronavirus desencadenando el síndrome respiratorio severo agudo coronavirus 2 (Sars-cov-2), que ocasiona la enfermedad del coronavirus 19 (Covid-19), originado en la provincia de Hubei, ciudad de Wuhan, en la República Popular de China, lo que ocasionó una pandemia global y una amenaza a la salud pública. Objetivo: Esta revisión sistemática tiene como objetivo determinar los efectos de la azitromicina, hidroxicloroquina e ivermectina en pacientes ambulatorios y hospitalizados con covid-19. Material y Métodos: La revisión está adherida a la guía PRISMA para revisiones sistemáticas. Se realizó una búsqueda bibliográfica de literatura en Pub Med /MEDLINE hasta el 04 de marzo de 2021, se evaluó estrategias de búsqueda mediante el programa del Manual Cochrane de revisiones sistémicas. Se utilizo el programa de Mendeley, para la gestionar referencias bibliográficas. Resultados: En la búsqueda inicial se registraron 832 estudios, de los que se incluyeron 17 publicaciones. Además, se incluyó un artículo secundario de la búsqueda adicional de los 17 artículos. La azitromicina y/o hidroxicloroquina aumentan la mortalidad y ocasionan eventos adversos, respecto a los grupos de atención habitual (27% vs 25%, OR, 1,9, IC 95% 0,97-1.23, p=015) y la ivermectina respecto al grupo control en la resolución de síntomas (82% vs 79%) y eventos adversos (52% vs 56%), de diversos estudios. Conclusiones: La azitromicina, hidroxicloroquina e ivermectina, no tienen efectos beneficiosos contra la covid-19 en pacientes ambulatorios y hospitalizados.
 
Publisher Universidad de Ciencias Médicas de Pinar del Río
 
Contributor
 
Date 2021-06-03
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion

 
Identifier http://revgaleno.sld.cu/index.php/ump/article/view/690
 
Source Universidad Médica Pinareña; Avances en línea; e690
Universidad Médica Pinareña; Avances en línea; e690
1990-7990
 
Language es
 
Relation http://revgaleno.sld.cu/index.php/ump/article/downloadSuppFile/690/157
http://revgaleno.sld.cu/index.php/ump/article/downloadSuppFile/690/158
http://revgaleno.sld.cu/index.php/ump/article/downloadSuppFile/690/159
http://revgaleno.sld.cu/index.php/ump/article/downloadSuppFile/690/160
http://revgaleno.sld.cu/index.php/ump/article/downloadSuppFile/690/161
http://revgaleno.sld.cu/index.php/ump/article/downloadSuppFile/690/162
/*ref*/Dhama K, Khan S, Tiwari R, Sircar Sh, Bhat S, Malik YS et al. Coronavirus disease 2019–COVID-19. Clin Microbiol Rev [Internet]. 2020 [citado 28/02/2021]; 33(4): 1-48. Doi: 10.1128/CMR.00028-20
/*ref*/Gralinski LE, Menachery VD. Return of the coronavirus: 2019-nCoV. Viruses [Internet]. 2020 [citado 28/02/2021]; 12(2): 135. Doi: 10.3390/v12020135.
/*ref*/Sharma A, Tiwari S, Deb M, Marty JL. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int J Antimicrob Agents [Internet]. 2020 [citado 28/02/2021]; 56(2): 106054. Doi: 10.1016/j.ijantimicag.2020.106054.
/*ref*/Bakadia BM., He F, Souho T, Lamboni L, Ullah MW, Boni BO et al. Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. Biomed Pharmacother [Internet]. 2021 [citado 28/02/2021]; 133: 111008. Doi: 10.1016/j.biopha.2020.111008.
/*ref*/Caly L., Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res [Internet]. 2020 [citado 28/02/2021]; 178: 104787. Doi: 10.1016/j.antiviral.2020.104787.
/*ref*/Perricone C, Triggianese P, Bartoloni E, Cafaro G, Bonifacio AF, Bursi R et al. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun [Internet]. 2020 [citado 28/02/2021]; 111: 102468. Doi: 10.1016/j.jaut.2020.102468.
/*ref*/Andreani J, Le Bideau M, Duflot I, Jardot P, Rolland C, Boxberger M, et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb Pathog [Internet]. 2020 [citado 28/02/2021]; 145: 104228. Doi: 10.1016/j.micpath.2020.104228.
/*ref*/Liang C, Tian L, Liu Y, Hui N, Qiao G, Li H, et al. A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir. Eur J Med Chem [Internet]. 2020 [citado 28/02/2021]; 201: 112527. Doi: 10.1016/j.ejmech.2020.112527.
/*ref*/Kaptein SJF, Jacobs S, Langendries L, Seldeslachts L, ter Horst S, Liesenborghs L, et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity. Proc Natl Acad Sci USA [Internet]. 2020 [citado 28/02/2021]; 117(43): 26955-26965. Doi: 10.1073/pnas.2014441117.
/*ref*/Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga V, Avezumet A, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med [Internet]. 2020 [citado 28/02/2021]; 383(21): 2041-2052. Doi: 10.1056/nejmoa2019014.
/*ref*/Furtado RHM, Berwanger O, Fonseca HA, Corrêa TD, Ferraz LR, Lapa MG, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet [Internet]. 2020 [citado 28/02/2021]; 396(10256): 959-967. Doi: 10.1016/S0140-6736(20)31862-6.
/*ref*/Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents [Internet]. 2020 [citado 28/02/2021]; 56(1): 106239. Doi: 10.1016/j.ijantimicag.2020.105949.
/*ref*/Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med [Internet]. 2020 [citado 28/02/2021]; 383(6): 517-525. Doi: 10.1056/nejmoa2016638.
/*ref*/Mitjà O, Corbacho-Monné M, Ubals M, Alemany A, Suñer C, Tebé C, et al. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. N Engl J Med [Internet]. 2021 [citado 28/02/2021]; 384(5): 417-427. Doi: 10.1056/nejmoa2021801.
/*ref*/Horby P, Mafhan M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med [Internet]. 2020 [citado 28/02/2021]; 383(21): 2030-2040. Doi: 10.1056/nejmoa2022926.
/*ref*/Self W, Semler M, Leither LM, Casey JD, Angus DC, Browe RG, et al. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients with COVID-19: A Randomized Clinical Trial. JAMA [Internet]. 2020 [citado 28/02/2021]; 324(21): 2165-2176. Doi: 10.1001/jama.2020.22240.
/*ref*/Abella B, Jolkovsky E, Biney BT, Uspal JE, Hyman M, Frank I, et al. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis among Health Care Workers: A Randomized Clinical Trial. JAMA Intern Med [Internet]. 2020 [citado 28/02/2021]; 181(2): 195-202. Doi: 10.1001/jamainternmed.2020.6319.
/*ref*/Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: Open label, randomised controlled trial. BMJ [Internet]. 2020 [citado 28/02/2021]; 369: 1849. Doi: 10.1136/bmj.m1849.
/*ref*/Abd-Elsalam S, Esmail E, Khalaf M, Abdo EF, Medhat MA, El Ghafar MSA, et al. Hydroxychloroquine in the treatment of COVID-19: A multicenter randomized controlled study. Am J Trop Med Hyg [Internet]. 2020 [citado 28/02/2021]; 103(3): 1635-1639. Doi: 10.4269/ajtmh.20-0873.
/*ref*/Skipper C, Pastick K, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, et al. Hydroxychloroquine in Nonhospitalized Adults with Early COVID-19: A Randomized Trial. Ann Intern Med [Internet]. 2020 [citado 28/02/2021]; 173(8): 623-631. Doi: 10.7326/M20-4207.
/*ref*/Sekhavati E, Jafari F, SeyedAlinaghi SA, Jamalimoghadamsiahkali S, Sadr S, Tabarestani M, et al. Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. Int J Antimicrob Agents [Internet]. 2020 [citado 01/03/2021]; 56(4): 106143. Doi: 10.1016/j.ijantimicag.2020.106143.
/*ref*/Shouman W. Prophylactic Ivermectin in COVID-19. Egipto. ClinicalTrials.gov. [Internet] [revisado 31 May 2020]. Disponible: https://clinicaltrials.gov/ct2/show/NCT04422561.
/*ref*/Lopez-Medina E, Lopez P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. Effect of Ivermectin on Time to Resolution of Symptoms among Adults with Mild COVID-19: A Randomized Clinical Trial. JAMA [Internet]. 2021 [citado 01/03/2021]; [Epub ahead of print]. Doi: 10.1001/jama.2021.3071.
/*ref*/Rajter J, Sherman M, Fatteh N, Vogel F, Sacks J, Rajter JJ. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study. Chest [Internet]. 2021 [citado 01/03/2021]; 159(1): 85-92: 10.1016/j.chest.2020.10.009.
/*ref*/Rahman MA, Iqbal SA, Islam MA, Niaz MK, Hussain T, Siddiquee TH. Comparison of viral clearance between ivermectin with doxycycline and hydroxychloroquine with azithromycin in COVID-19 patients. J Bangladesh Coll Physicians Surg [Internet]. 2020 [citado 01/03/2021]; [Epub ahead of print]. Doi: 10.3329/jbcps.v38i0.47514.
/*ref*/Mahmud R. Clinical Trial of Ivermectin plus Doxycycline for the Treatmet of Confirmed Covid-19 Infection. ClinicalTrials.gov. [Internet] [Revisado 30 Set 2020]. Disponible: https://www.cochranelibrary.com/es/central/doi/10.1002/central/CN-02163042/full.
 
Rights Copyright (c) 2021 El autor y garantizarán a la revista el derecho de primera publicación de su obra
http://creativecommons.org/licenses/by-nc/4.0
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library